Pharmafile Logo
Pharmafocus logo
Advanced Search

Johnson & Johnson

Showing 15 posts of 137 posts found.

pharmafocus_march_cover

The March 2017 issue of Pharmafocus is now live!

February 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, FDA, Johnson & Johnson, MSD, Roche, Trump, crispr, immunotherapy, opdivo

The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing …

News
handshake-2056023_960_720

Integra bids $1.045 billion for J&J’s neurosurgery business

February 16, 2017
Sales and Marketing Codman, Integra, J&J, JJ, Johnson & Johnson

Integra, a medical technology company, have announced that it has made a binding offer to acquire Johnson & Johnson’s Codman …

News
money-256281_960_720

Five most talked about mergers and acquisitions of 2016

January 27, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Bayer, Boehringer, Johnson & Johnson, Sanofi, Teva, acquisition, mergers, monsanto, pharma

2017 has kicked off with a bang – as Johnson & Johnson confirmed a $30 billion deal to takeover of …

Feature
jj

J&J finally seals $30 billion deal for Actelion

January 26, 2017
Sales and Marketing Actelion, Janssen, Johnson & Johnson

Johnson & Johnson has, as expected, wrapped up the deal to acquire Actelion in a deal worth $30 billion, working …

News
jj_sign_on_wall

J&J to reveal drug price increases next month

January 16, 2017
Sales and Marketing Johnson & Johnson

Next month, Johnson & Johnson will reveal the average price increases of its prescription drugs in a move to increase …

News
jj_2johnson_and_johnson

Actelion acquisition hokey-cokey continues with J&J returning to table

December 22, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, Johnson & Johnson, Sanofi

The Actelion takeover saga continues with Johnson & Johnson back in the game, and now re-entering into exclusive negotiations. Actelion …

News

J&J’s largest India site to finally operate by 2018

December 20, 2016
Manufacturing and Production India, Johnson & Johnson

Johnson & Johnson has reportedly announced that its manufacturing plant in Telangana, India, its largest site in the country, is …

News
actelion

Sanofi eyes Actelion merger as J&J backs down

December 14, 2016
Medical Communications, Research and Development, Sales and Marketing Actelion, Johnson & Johnson, Sanofi

After days of negotiations, Johnson and Johnson has stepped down from its attempts to acquire Swiss blood-pressure specialist Actelion, while …

News
jj_2johnson_and_johnson

J&J and Genmab’s drug races to second line treatment approval

November 22, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, Johnson & Johnson, darzalex, multiple myeloma

Janssen, a part of Johnson & Johnson, and Genmab have announced that their multiple myeloma drug Darzalex (daratumumab) has been …

News
clinical_trial

GSK/J&J release how their drug measures up against Humira

November 18, 2016
Medical Communications, Research and Development GSK, Humira, Janssen, Johnson & Johnson, sirukumab

GlaxoSmithKline and Janssen, part of Johnson & Johnson, released the results of their two Phase III trials exploring treatment options …

News
janssen_latest_logo_on_sign_closer

Janssen’s Crohn’s treatment licensed for UK use

November 16, 2016
Research and Development, Sales and Marketing Chrohn's disease, J&J, JJ, Janssen, Johnson & Johnson, Stelara

Janssen, a subsidiary of Johnson & Johnson, has announced that its treatment Stelara (ustekinumab) is now licensed by the European …

News
janssen_stairs

Collaboration on new therapeutic vaccine for HIV shows promise

November 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Janssen, Johnson & Johnson

Janssen, part of Johnson & Johnson, released details on 9 November of the results of a new study looking into …

News
code

BenevolentAI announces licensing agreement with Janssen

November 8, 2016
Research and Development Janssen, Johnson & Johnson, artificial intelligence

BenevolentAI, a British artificial intelligence company, announced a licensing agreement to develop a select number of drug candidates with Janssen, …

News
pfizer_sky

Pfizer sets release date for rival to J&J’s blockbuster drug

October 18, 2016
Manufacturing and Production J&J, JJ, Johnson & Johnson, Pfizer, Remicade, inflectra

Pfizer have announced that they will begin shipping their rival to Johnson & Johnson’s Remicade by the end of November. …

News
astrazeneca_building_white

AstraZeneca sells off third drug in five days

October 7, 2016
Medical Communications AstraZeneca, Cilag GmbH, Johnson & Johnson, Rhinocort Aqua

AstraZeneca have completed a third sell off in the course of one week by divesting rights to Rhinocort Aqua outside …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024